|Institution||School of Medicine and Dentistry|
|Department||Pathology and Laboratory Medicine|
|Address||University of Rochester Medical Center|
School of Medicine and Dentistry
601 Elmwood Ave, Box 626
Rochester NY 14642
||The First National Conference for outstanding young and middle age basic scientists in Beijing, PR China|
||A two-year fellowship from Boehringer Ingelheim Foundation of Germany.|
||Sowell-Huggins award from The University of Texas MD Anderson Cancer Center Graduate School of Biomedical Sciences in Houston.|
Dr. Tang's Ph.D. research at the University of Texas MD Anderson Cancer Center involved tumor necrosis factor signal transduction and protein processing. From 1995-98 she served as a postdoctoral fellow, studying growth inhibition of glioma cells by antisense TGF-alpha. Since her residency at North Shore and her surgical pathology fellowship at Yale, she has focused on early breast carcinogenesis.
At Rochester, Dr. Tang was the recipient of an Empire Clinical Research Investigator Program (ECRIP) award to fund a study of molecular markers that may predict a subgroup of ductal carcinoma in situ (DCIS) with high risk of progression to invasive ductal carcinoma (IDC). DCIS is a heterogeneous group of lesions that accounts over 20% of breast carcinoma diagnosed annually which has a 14-53% chance of progression to IDC over a 10-year period.
She is currently working to identify a group of biomarkers that will predict a subset of breast tumors with a high risk of bone metastasis. She is using immunocytochemistry, a common and relatively inexpensive form of analysis, in the hope that her findings may be easily translated into clinical practice, allowing more aggressive treatment of tumors with greater risk of metastasis.
People who are also in this person's primary department.